...
首页> 外文期刊>BMC Infectious Diseases >Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza
【24h】

Comparison of a novel microcrystalline tyrosine adjuvant with aluminium hydroxide for enhancing vaccination against seasonal influenza

机译:新型微晶酪氨酸佐剂与氢氧化铝增强季节性流感疫苗接种的比较

获取原文
           

摘要

Background Vaccination against seasonal influenza strains is recommended for “high risk” patient groups such as infants, elderly and those with respiratory or circulatory diseases. However, efficacy of the trivalent influenza vaccine (TIV) is poor in many cases and in the event of an influenza pandemic, mono-valent vaccines have been rapidly developed and deployed. One of the main issues with use of vaccine in pandemic situations is the lack of a suitable quantity of vaccine early enough during the pandemic to exert a major influence on the transmission of virus and disease outcome. One approach is to use a dose-sparing regimen which inevitably involves enhancing the efficacy using adjuvants. Methods In this study we compare the use of a novel microcrystalline tyrosine (MCT) adjuvant, which is currently used in a niche area of allergy immunotherapy, for its ability to enhance the efficacy of a seasonal TIV preparation. The efficacy of the MCT adjuvant formulation was compared to alum adjuvanted TIV and to TIV administered without adjuvant using a ferret challenge model to determine vaccine efficacy. Results The MCT was found to possess high protein-binding capacity. In the two groups where TIV was formulated with adjuvant, the immune response was found to be higher (as determined by HAI titre) than vaccine administered without adjuvant and especially so after challenge with a live influenza virus. Vaccinated animals exhibited lower viral loads (as determined using RT-PCR) than control animals where no vaccine was administered. Conclusions The attributes of each adjuvant in stimulating single-dose protection against a poorly immunogenic vaccine was demonstrated. The properties of MCT that lead to the reported effectiveness warrants further exploration in this and other vaccine targets - particularly where appropriate immunogenic, biodegradable and stable alternative adjuvants are sought.
机译:背景技术对于婴儿,老年人以及患有呼吸道或循环系统疾病的“高风险”患者群,建议对季节性流感毒株进行疫苗接种。但是,在许多情况下,三价流感疫苗(TIV)的功效很差,一旦发生流感大流行,单价疫苗已迅速开发和部署。在大流行情况下使用疫苗的主要问题之一是在大流行期间缺乏足够早的适量疫苗以对病毒的传播和疾病后果产生重大影响。一种方法是使用节省剂量的方案,该方案不可避免地涉及使用佐剂来增强功效。方法在本研究中,我们比较了新型微晶酪氨酸(MCT)佐剂的使用,该佐剂目前可用于变态免疫治疗的利基领域,因为它具有增强季节性TIV制剂功效的能力。使用雪貂攻击模型将MCT佐剂制剂的功效与明矾佐剂的TIV和不佐剂施用的TIV进行比较,以确定疫苗功效。结果发现MCT具有高蛋白结合能力。在用佐剂配制TIV的两组中,发现免疫应答(通过HAI滴度确定)要比不使用佐剂给予的疫苗更高,尤其是在用活流感病毒攻击后。与未接种疫苗的对照动物相比,接种疫苗的动物显示出较低的病毒载量(使用RT-PCR测定)。结论证明了每种佐剂在刺激针对免疫原性差的疫苗的单剂量保护中的特性。导致报道的有效性的MCT特性值得进一步针对该疫苗靶标和其他疫苗靶标进行探索-特别是在寻求适当的免疫原性,可生物降解和稳定的替代佐剂的地方。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号